These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
94 related articles for article (PubMed ID: 8373527)
21. Vaccines and passive immunological approaches for the control of fertility and hormone-dependent cancers. Talwar GP Immunol Rev; 1999 Oct; 171():173-92. PubMed ID: 10582171 [TBL] [Abstract][Full Text] [Related]
22. The present and future of immunologic approaches to contraception. Talwar GP Int J Gynaecol Obstet; 1978; 15(5):410-4. PubMed ID: 28974 [TBL] [Abstract][Full Text] [Related]
23. An overview of adjuvant formulations and delivery systems. García A; De Sanctis JB APMIS; 2014 Apr; 122(4):257-67. PubMed ID: 23919674 [TBL] [Abstract][Full Text] [Related]
24. [Controversial contraception: immunization against human chorionic gonadotrophin. Consultancy of Maternal Health and Family Planning of the Netherlands Association for Obstetrics and Gynecology]. Wildschut HI Ned Tijdschr Geneeskd; 1996 Mar; 140(13):722-5. PubMed ID: 8668254 [No Abstract] [Full Text] [Related]
25. Particulate delivery systems for vaccines: what can we expect? Bramwell VW; Perrie Y J Pharm Pharmacol; 2006 Jun; 58(6):717-28. PubMed ID: 16734973 [TBL] [Abstract][Full Text] [Related]
26. The Immunotherapeutics and Vaccine Summit - CHI's fifth annual meeting - novel vaccines: adjuvants and delivery systems: part 2. Jones SD IDrugs; 2010 Oct; 13(10):692-4. PubMed ID: 20878589 [TBL] [Abstract][Full Text] [Related]
27. Liposomal vaccine delivery systems. Henriksen-Lacey M; Korsholm KS; Andersen P; Perrie Y; Christensen D Expert Opin Drug Deliv; 2011 Apr; 8(4):505-19. PubMed ID: 21413904 [TBL] [Abstract][Full Text] [Related]
28. Relevance of immuno-contraceptive vaccines for population control. I. Hormonal immunocontraception. Gupta SK; Koothan PT Arch Immunol Ther Exp (Warsz); 1990; 38(1-2):47-60. PubMed ID: 2126920 [TBL] [Abstract][Full Text] [Related]
29. Liposomes act as stronger sub-unit vaccine adjuvants when compared to microspheres. Kirby DJ; Rosenkrands I; Agger EM; Andersen P; Coombes AG; Perrie Y J Drug Target; 2008 Aug; 16(7):543-54. PubMed ID: 18686124 [TBL] [Abstract][Full Text] [Related]
30. Adjuvants and delivery systems in veterinary vaccinology: current state and future developments. Heegaard PM; Dedieu L; Johnson N; Le Potier MF; Mockey M; Mutinelli F; Vahlenkamp T; Vascellari M; Sørensen NS Arch Virol; 2011 Feb; 156(2):183-202. PubMed ID: 21170730 [TBL] [Abstract][Full Text] [Related]
31. Delivery systems for molecular vaccination. Sheikh NA; al-Shamisi M; Morrow WJ Curr Opin Mol Ther; 2000 Feb; 2(1):37-54. PubMed ID: 11249651 [TBL] [Abstract][Full Text] [Related]
32. Transcutaneous vaccines: novel advances in technology and delivery for overcoming the barriers. Li N; Peng LH; Chen X; Nakagawa S; Gao JQ Vaccine; 2011 Aug; 29(37):6179-90. PubMed ID: 21740946 [TBL] [Abstract][Full Text] [Related]
38. The use of soluble polymers and polymer microparticles to provide improved vaccine responses after parenteral and mucosal delivery. Davis SS Vaccine; 2006 Apr; 24 Suppl 2():S2-7-10. PubMed ID: 16823907 [TBL] [Abstract][Full Text] [Related]